Has the Malaysian Pharma Industry valuation changed over the past few years?

Investors are pessimistic on the Malaysian Pharmaceuticals industry, indicating that they anticipate long term growth rates will be lower than they have historically. The industry is trading at a PE ratio of 12.1x which is lower than its 3-year average PE of 14.0x. The 3-year average PS ratio of 1.5x is higher than the industry's current PS ratio of 1.2x.

Which industries have driven the changes within the Malaysian Healthcare industry?

There are no additional sub-industries under this industry.

Malaysian (KLSE) Pharma Industry Analysis

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Sat, 19 Sep 2026	RM 2.2b	RM 1.9b	RM 182.7m	10.7x	11.9x	1.2x
Mon, 17 Aug 2026	RM 2.3b	RM 1.9b	RM 168.0m	12.6x	13.5x	1.2x
Wed, 15 Jul 2026	RM 2.2b	RM 1.9b	RM 168.0m	12.4x	13.3x	1.2x
Fri, 12 Jun 2026	RM 2.3b	RM 1.9b	RM 168.0m	13x	13.5x	1.2x
Sun, 10 May 2026	RM 2.4b	RM 1.9b	RM 169.4m	14.2x	14x	1.3x
Tue, 07 Apr 2026	RM 2.3b	RM 1.9b	RM 169.4m	13.9x	13.8x	1.2x
Thu, 05 Mar 2026	RM 2.5b	RM 1.9b	RM 169.4m	14.5x	15x	1.3x
Sat, 31 Jan 2026	RM 2.4b	RM 1.9b	RM 166.4m	14.1x	14.7x	1.3x
Mon, 29 Dec 2025	RM 4.3b	RM 2.8b	RM 231.9m	14.5x	18.3x	1.5x
Wed, 26 Nov 2025	RM 4.2b	RM 2.8b	RM 230.7m	14.6x	18.3x	1.5x
Fri, 24 Oct 2025	RM 4.1b	RM 2.8b	RM 223.3m	15.3x	18.6x	1.5x
Sun, 21 Sep 2025	RM 4.2b	RM 2.8b	RM 223.3m	15.9x	18.8x	1.5x
Tue, 19 Aug 2025	RM 4.2b	RM 2.8b	RM 231.0m	15.6x	18.2x	1.5x
Thu, 17 Jul 2025	RM 4.2b	RM 2.8b	RM 230.3m	16x	18.2x	1.5x
Sat, 14 Jun 2025	RM 4.0b	RM 2.8b	RM 230.3m	15.8x	17.5x	1.4x
Mon, 12 May 2025	RM 3.8b	RM 2.8b	RM 221.0m	17x	17.4x	1.4x
Wed, 09 Apr 2025	RM 3.6b	RM 2.8b	RM 221.0m	16.1x	16.3x	1.3x
Fri, 07 Mar 2025	RM 3.9b	RM 2.8b	RM 221.0m	16.3x	17.4x	1.4x
Sun, 02 Feb 2025	RM 4.1b	RM 2.7b	RM 223.9m	16.6x	18.3x	1.5x
Tue, 31 Dec 2024	RM 4.2b	RM 2.7b	RM 223.9m	17.3x	18.7x	1.5x
Thu, 28 Nov 2024	RM 4.2b	RM 2.7b	RM 234.3m	14x	18x	1.5x
Sat, 26 Oct 2024	RM 4.4b	RM 2.7b	RM 230.0m	14.2x	19.1x	1.6x
Mon, 23 Sep 2024	RM 4.3b	RM 2.7b	RM 230.0m	14.8x	18.9x	1.6x
Wed, 21 Aug 2024	RM 4.4b	RM 2.7b	RM 545.0m	13.2x	8x	1.6x
Fri, 19 Jul 2024	RM 4.4b	RM 2.6b	RM 541.3m	13x	8.2x	1.7x
Sun, 16 Jun 2024	RM 4.5b	RM 2.6b	RM 541.3m	13.3x	8.4x	1.7x
Tue, 14 May 2024	RM 4.9b	RM 2.6b	RM 559.3m	12.4x	8.8x	1.9x
Thu, 11 Apr 2024	RM 4.6b	RM 2.6b	RM 559.3m	12.3x	8.1x	1.7x
Sat, 09 Mar 2024	RM 4.5b	RM 2.6b	RM 559.3m	12.6x	8x	1.7x
Mon, 05 Feb 2024	RM 4.5b	RM 2.6b	RM 584.9m	12.1x	7.7x	1.8x
Wed, 03 Jan 2024	RM 4.2b	RM 2.6b	RM 584.9m	12.4x	7.2x	1.7x
Fri, 01 Dec 2023	RM 4.1b	RM 2.6b	RM 584.4m	12.3x	7.1x	1.6x
Sun, 29 Oct 2023	RM 4.2b	RM 2.6b	RM 604.4m	12x	7x	1.6x
Tue, 26 Sep 2023	RM 4.3b	RM 2.6b	RM 604.4m	12.7x	7.2x	1.7x


MY Market	-0.78%
Healthcare	0.78%
Pharma	-2.29%
Pharma	-2.29%

	Company	Last Price	7D	1Y	Valuation
	RHONEMA Rhone Ma Holdings Berhad	RM 0.68	3.1% +RM 4.4m	3.1%	PE10.4x
	PLABS PeterLabs Holdings Berhad	RM 0.23	2.3% +RM 1.4m	-16.7%	PS0.6x

Announcement • Sep 01

Y.S.P. Southeast Asia Holding Berhad Announces Appointment of Mr. Ng Kim Kiat to Independent Director, Effective September 1, 2026

Y.S.P. SOUTHEAST ASIA HOLDING BERHAD announced that Mr. Ng Kim Kiat had been appointed as Independent Director, effective September 1, 2026. Mr. Ng Kim Kiat, aged 56, is Malaysian. He holds a Bachelor of Accountancy (Honors) from Universiti Putra Malaysia (formerly known as Universiti Pertanian Malaysia). He is a Chartered Accountant (Malaysia) or CA(M) from the Malaysian Institute of Accountants (MIA) and an Associate member of the Chartered Tax Institute of Malaysia (CTIM) or ATII(M). Mr. Ng started his career as an audit assistant in an audit firm, namely Y.S. Wong & Co in May 1995, carrying out audits of financial statements for private companies and related income tax reporting. He was subsequently promoted to audit semi-senior in January 1996 before leaving the firm in February 1997. In March 1997, he joined another audit firm, namely SC Lim, Ng & Co. (formerly known as S.C. Lim & Co) as an audit senior. Over the years, he rose through the ranks and was promoted to its audit partner in September 2000, whereby he was also responsible for the firm business development activities across its offices in Muar and Kuala Lumpur. Meanwhile, Mr. Ng also joined Crowe Malaysia (formerly known as Horwath or Crowe Horwath) in January 2009 as its audit partner, whereby he oversaw its entire operation of the newly opened Muar branch. Crowe Malaysia was converted into a limited liability partnership, namely Crowe Malaysia PLT in January 2019. In December 2019, he withdrew as partner from SC Lim, Ng & Co. to focus his audit career with Crowe Malaysia PLT. In April 2021, he was made a director of Kairous Acquisition Corp. Limited, a special purpose acquisition company incorporated in Cayman Islands and listed on the NASDAQ Stock Exchange in the United States of America, a position which he has since relinquished in November 2023. In October 2022, Mr. Ng was made Partner of Silver Ocean PLT, a firm providing corporate recovery services, and in November 2022, he was made Partner in Crowe Muar Advisory PLT, also a firm providing corporate recovery services. In May 2023, he was also made Partner of Serling Academy PLT, a firm providing training services. He left Crowe Malaysia PLT in December 2023 and Crowe Muar Advisory PLT in January 2024 and rejoined SC Lim, Ng & Co. PLT (which was converted from SC Lim, Ng & Co in September 2023) as its audit partner in January 2024. He has served as director in Vetece Holdings Berhad.

Malaysian (KLSE) Pharma Industry Analysis

Industry Valuation and Performance

Industry Trends

Top Stock Gainers and Losers

Latest News

Y.S.P. Southeast Asia Holding Berhad Announces Appointment of Mr. Ng Kim Kiat to Independent Director, Effective September 1, 2026

Full year 2026 earnings released: RM0.006 loss per share (vs RM0.006 profit in FY 2025)

Full year 2026 earnings released: EPS: RM0.27 (vs RM0.29 in FY 2025)

First half dividend of RM0.015 announced

Second quarter 2026 earnings released: EPS: RM0.016 (vs RM0.016 in 2Q 2025)